查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929526

全球牙科抗发炎药物市场（按药物分类、给药途径、剂型、应用、最终用途和分销管道划分）预测（2026-2032年）

Anti-inflammatory Drugs for Dental Market by Drug Class, Route Of Administration, Dosage Form, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，牙科抗发炎药物市场价值将达到 16.5 亿美元，到 2026 年将成长至 17.8 亿美元，到 2032 年将达到 32.4 亿美元，年复合成长率为 10.08%。

关键市场统计数据
基准年 2025 16.5亿美元
预计年份：2026年 17.8亿美元
预测年份 2032 32.4亿美元
复合年增长率 (%) 10.08%

从策略角度概述了现代抗发炎疗法如何透过在疗效、安全性和配方方面的进步来重新定义手术全期牙科护理。

抗发炎疗法是现代牙科诊疗的核心，可支持从常规拔牙到复杂牙周治疗等多种诊疗程序。其作用不仅限于控制症状，还能改善手术全期疗效，减少发炎相关併发症，并维持患者术后恢復的舒适度。临床医生正日益将这些药物整合到以安全性、快速康復和减少阿片类药物依赖性为优先考虑的多方面镇痛通讯协定中。同时，製药研发商和经销商正致力于製剂创新和优化给药途径，以满足不同的临床需求。

不断发展的临床实践、製剂创新、监管政策的明确性以及供应链的韧性如何共同重塑牙科抗炎疗法的提供方式

牙科抗发炎治疗领域正经历着一场变革，其驱动力包括临床实践的改变、製剂创新以及监管的加强。临床医师正采用多管齐下的疼痛管理方法，结合局部和全身用药，以最大限度地减少鸦片类药物的使用，并加速功能恢復。这种临床转变促使生产商投资研发速效、标靶给药系统，并将耐受性作为在竞争激烈的治疗领域中脱颖而出的关键因素。

2025年美国关税调整对牙科抗发炎疗法筹资策略、业务地点和供应链合规性的影响

计划于2025年生效的关税政策和贸易措施正迫使牙科治疗药物的生产商和经销商重新评估其采购、製造地和库存策略。进口关税的变化以及相关的合规义务加剧了全球供应链的成本敏感性，尤其是活性药物成分和特殊辅料，这些成分通常需要跨境采购。为此，许多企业正在考虑近岸外包、双重采购以及增加缓衝库存，以降低时间风险并维持牙科诊所和医院的产品供应。

透过对药物类别、剂型、通路、最终用户和临床应用进行综合細項分析，将市场发展和分销选择连结起来。

关键细分趋势揭示了不同药物类别、给药途径、剂型、分销管道、最终用户和应用领域所带来的不同的临床和商业性机会。依药物类别划分，市场结构包括皮质类固醇和非类固醇消炎剂（NSAIDs）。皮质类固醇的代表药物包括地塞米松和泼尼松龙，而NSAIDs则包括Ibuprofen、酮洛芬和萘普生。这种治疗方法的多样性影响着牙科实践中的处方模式和安全考量，临床医生会根据发炎的特征、患者的合併症以及手术情况来选择药物。

影响临床应用、监管协调、製造地和分销策略的区域趋势

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素、监管重点和分销模式，每个地区都展现出独特的临床实践和市场结构。在美洲，临床上对门诊牙科手术的关注以及对阿片类药物管理的日益重视，促使人们倾向于选择口服和局部抗炎策略；而支付机制和采购框架则影响着通路的选择和药品目录的收录。

企业如何透过配方创新、证据产生、供应链强化和与临床医生合作来实现差异化，从而抓住牙科护理领域的机会

牙科抗发炎治疗领域的竞争重点在于推进製剂科学、确保差异化的给药机制以及优化生产和分销网络。主要企业正投资于临床证据的积累，以支持牙科特定适应症，并证明其在起效速度、持续时间和安全性方面优于传统疗法。製药开发商和医疗设备製造商之间正在建立策略联盟，以将局部和局部给药技术的创新转化为临床可行的解决方案。

给经营团队的实用建议：使研发、监管策略和供应链韧性与临床需求和分销实际情况保持一致

产业领导者可以透过将研发、监管和商业活动与临床需求和供应链实际情况相结合，将当前趋势转化为竞争优势。应优先开发临床差异化的局部局部剂型，以减少全身暴露并促进快速恢復，同时确保针对牙科适应症的可靠安全性数据。此外，还应投资于比较临床证据和实用工具，以帮助临床医生采用新的通讯协定并为采购决策的变更提供基础。

采用透明的调查方法，结合临床医师访谈、监管审查、临床文献综合和操作检验，得出基于证据的结论。

本研究整合了专家访谈、同侪审查的临床文献、监管指导文件和检验的营运情报，建构了强有力的证据基础。透过对牙科临床医生、处方笺负责人、采购经理和生产专家进行结构化访谈，收集了来自临床、商业和供应链领域的实际观点。这些定性见解与已发表的临床研究和监管指导文件进行三角验证，检验治疗定位、安全性考虑因素和剂量偏好。

透过整合临床重点、製剂创新、监管细微差别和营运弹性等因素，为策略决策提供支援。

牙科抗发炎治疗药物在临床需求、製剂研发机会和供应链复杂性之间占据着策略性性交汇点。临床医生越来越关注以病人安全、快速康復和减少对全身性阿片类药物依赖为优先的多方面治疗方法，这推动了人们对局部用药製剂和明确给药通讯协定的兴趣。同时，製造商和经销商必须应对监管审查、关税导致的供应链变化以及不断变化的经销管道趋势，同时还要提供可在包括牙科诊所、医院和居家医疗机构在内的所有场所使用的差异化产品。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按药物类别分類的牙科抗发炎药物市场

  • 皮质类固醇
    • 地塞米松
    • 泼尼松龙
  • 非类固醇消炎剂
    • Ibuprofen
    • 酮洛芬
    • 萘普生

9. 按给药途径分類的牙科抗发炎药物市场

  • 注射
  • 口服
  • 外用

第十章 按剂型分類的牙科抗发炎药物市场

  • 凝胶
  • 注射
  • 漱口水
  • 药片

第十一章 按应用领域分類的牙科抗发炎药物市场

  • 牙周疼痛
  • 术后疼痛
  • 术前疼痛

第十二章 按最终用户分類的牙科抗发炎药物市场

  • 牙医诊所
  • 居家照护
  • 医院

第十三章 按分销管道分類的牙科抗发炎药市场

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 各地区牙科抗发炎药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 牙科抗发炎药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国牙科抗发炎药物市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国牙科抗发炎药物市场

第十八章 中国牙科抗发炎药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Church & Dwight Co. Inc.
  • Colgate-Palmolive Company
  • Dentsply Sirona Inc.
  • GlaxoSmithKline plc
  • Haleon plc
  • Henry Schein Inc.
  • Ivoclar Vivadent AG
  • Johnson & Johnson
  • Patterson Companies Inc.
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Septodont
  • Sunstar Suisse SA
  • VOCO GmbH
Product Code: MRR-0A38069517F6

The Anti-inflammatory Drugs for Dental Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.08%, reaching USD 3.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.24 billion
CAGR (%) 10.08%

A strategic overview of how contemporary anti-inflammatory therapies are redefining perioperative dental care through efficacy, safety, and formulation advances

Anti-inflammatory therapies are central to contemporary dental practice, supporting procedures from routine extractions to complex periodontal interventions. Their role extends beyond symptom suppression to shaping perioperative outcomes, reducing inflammation-driven complications, and supporting patient comfort during recovery. Clinicians increasingly integrate these agents into multimodal analgesia protocols that prioritize safety, rapid recovery, and reduced opioid reliance. Concurrently, pharmaceutical developers and distributors focus on formulation innovation and route optimization to meet diverse clinical needs.

Recent developments in pharmacology and formulation science have expanded the practical toolkit available to dental professionals. Topical gels and mouthwashes offer localized relief with minimized systemic exposure, while oral and injectable options permit dose flexibility and rapid onset for acute postoperative pain. Regulatory scrutiny of safety profiles, particularly related to systemic corticosteroids and nonsteroidal agents, has sharpened prescriber attention to indications, contraindications, and appropriate duration of therapy. As a result, decision makers across clinical, procurement, and product development functions are prioritizing evidence-based protocols that balance efficacy with tolerability.

This introduction frames anti-inflammatory agents not simply as adjuvants for symptomatic care but as strategic clinical tools that influence outcomes, patient satisfaction, and practice quality metrics. Understanding their therapeutic scope, administration routes, and implications for dental workflows sets the stage for deeper analysis of emerging trends, policy shifts, and supply chain dynamics addressed in subsequent sections.

How clinical practice evolution, formulation innovation, regulatory clarity, and supply chain resilience are jointly reshaping dental anti-inflammatory therapy provision

The landscape for dental anti-inflammatory therapeutics is undergoing transformative shifts driven by clinical practice changes, formulation innovation, and heightened regulatory focus. Clinicians are adopting multimodal pain management approaches that combine localized topical applications with systemic agents to minimize opioid exposure and accelerate functional recovery. This clinical pivot encourages manufacturers to invest in fast-acting, targeted delivery systems and to prioritize tolerability as a differentiator in crowded therapeutic categories.

Innovation in dosage forms has accelerated, with gels and mouthwashes being optimized for mucosal adhesion and sustained local effect, while injectable formulations are being refined for controlled release and lower systemic burden. Concurrently, adoption of digital health tools and tele-dentistry is altering how prescriptions are issued and monitored, creating demand for products that support remote adherence tracking and simplified administration regimens. Regulatory agencies are responding with clearer guidance on indications, labeling for dental-specific use cases, and safety monitoring for agents with systemic risks.

Supply chain resilience has become a competitive axis as manufacturers reassess sourcing strategies, quality assurance processes, and distribution partnerships to ensure continuity across channels. Together, these shifts are converging to create opportunities for clinically differentiated products, streamlined distribution models, and integrated care pathways that emphasize predictable, patient-centered outcomes.

Implications of the 2025 United States tariff adjustments on sourcing strategies, operational footprints, and supply chain compliance across dental anti-inflammatory therapies

Tariff policy and trade measures announced for implementation in 2025 are prompting manufacturers and distributors serving dental therapeutics to revisit sourcing, manufacturing footprint, and inventory strategies. Changes to import duties and related compliance obligations increase the cost sensitivity of global supply chains, particularly for active pharmaceutical ingredients and specialized excipients frequently sourced across borders. In response, many organizations are exploring near-shoring, dual-sourcing, and increased buffer inventories to mitigate timing risk and maintain product availability for dental practices and hospitals.

Beyond immediate cost implications, tariffs influence long-term strategic decisions about where to locate value-added activities such as formulation, packaging, and final assembly. Organizations reassessing their footprint are weighing the trade-offs between higher local operating costs and the benefits of reduced cross-border exposure, faster time-to-market, and simplified regulatory interactions. These trade-offs affect pricing strategies, distribution agreements, and the competitiveness of import-dependent product lines.

Regulatory compliance and customs documentation have become more prominent operational priorities, increasing demand for robust trade compliance teams and digital tracking systems that provide end-to-end visibility. For stakeholders in the dental therapeutics ecosystem, these adjustments underscore the necessity of integrated commercial and supply chain planning to preserve continuity of care for patients and to protect margins under shifting policy environments.

Comprehensive segmentation insights linking drug classes, delivery formats, channels, end users, and clinical applications to strategic development and distribution choices

Key segmentation dynamics reveal differentiated clinical and commercial opportunities across drug classes, administration routes, dosage forms, distribution channels, end users, and applications. Based on drug class, the landscape encompasses corticosteroids and nonsteroidal anti-inflammatory drugs; corticosteroids are further characterized by agents such as dexamethasone and prednisolone, while the nonsteroidal category includes ibuprofen, ketoprofen, and naproxen. This therapeutic diversity influences prescribing patterns and safety considerations in dental practice, with clinicians selecting agents according to inflammation profile, patient comorbidities, and procedural context.

Based on route of administration, treatment options span injectable, oral, and topical formats, each presenting unique advantages for onset of action, systemic exposure, and ease of use. Based on dosage form, the available modalities include gels, injections, mouthwashes, and tablets, and each form factor has implications for adherence, localized efficacy, and formulation challenges. Distribution channels range across hospital pharmacy, online pharmacy, and retail pharmacy, and channel selection impacts procurement workflows, stocking policies, and patient access.

End users for these therapies include dental clinics, home care settings, and hospitals, with each segment demanding different packaging, dosing instructions, and patient education materials. In terms of application, agents are utilized for periodontal pain, postoperative pain, and preoperative pain management, and clinical guidelines shape appropriate use across those scenarios. Taken together, these segmentation lenses provide actionable insight into where clinical needs, product design, and distribution strategy intersect to create opportunities for targeted innovation and value delivery.

Regional dynamics that determine clinical adoption, regulatory alignment, manufacturing footprint, and distribution strategies across global dental care geographies

Regional dynamics shape demand drivers, regulatory priorities, and distribution models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each exhibiting distinct clinical practices and market structures. In the Americas, clinical emphasis on ambulatory dental procedures and heightened focus on opioid stewardship steer preferences toward oral and topical anti-inflammatory strategies, while payer mechanisms and procurement frameworks influence channel adoption and formulary inclusion.

Europe, Middle East & Africa present a heterogeneous regulatory and clinical landscape in which national guidelines and varying reimbursement models affect adoption velocity for novel formulations and off-label dental indications. Regulatory harmonization efforts in certain economic blocs coexist with localized standards that require tailored compliance and labeling strategies. In contrast, the Asia-Pacific region is notable for rapid clinical adoption of novel dosage forms and an expanding manufacturing base that supports competitive production of both active ingredients and finished formulations, though regulatory pathways and quality expectations vary widely across jurisdictions.

These regional distinctions influence R&D prioritization, distribution partnerships, and supply chain design. Aligning product design and go-to-market approaches with regional clinical practices and regulatory realities enhances adoption potential and mitigates risks associated with cross-border distribution and differing standards of care.

How players are differentiating through formulation innovation, evidence generation, supply chain fortification, and clinician engagement to capture dental therapeutic opportunities

Competitive activity among companies engaged in dental anti-inflammatory therapeutics centers on advancing formulation science, securing differentiated delivery mechanisms, and optimizing manufacturing and distribution networks. Leading organizations are investing in clinical evidence generation to support dental-specific labeling and to demonstrate advantages in onset, duration, and safety relative to legacy options. Strategic collaborations between pharmaceutical developers and device manufacturers are emerging to convert topical and localized delivery innovations into practice-ready solutions.

Operationally, companies are strengthening their supply chain resilience through supplier diversification, quality systems modernization, and digital traceability to manage regulatory scrutiny and reduce exposure to single-source disruptions. On the commercial front, efforts to engage clinicians via targeted education, real-world evidence dissemination, and streamlined sample and procurement processes are increasingly important. Distribution strategies are also shifting, with some organizations expanding direct-to-clinic capabilities while others deepen partnerships with hospital and retail pharmacy networks to ensure product availability across care settings.

Collectively, these company-level moves emphasize differentiation through clinically meaningful innovation, disciplined operational execution, and collaborative approaches to market access that align with evolving dental practice patterns.

Actionable recommendations for executives to align R&D, regulatory strategy, and supply chain resilience with clinician needs and distribution realities

Industry leaders can convert current dynamics into competitive advantage by aligning R&D, regulatory, and commercial activities with clinical practice needs and supply chain realities. Prioritize development of clinically differentiated topical and localized delivery forms that reduce systemic exposure and support rapid recovery, while ensuring robust safety data tailored to dental indications. Simultaneously, invest in comparative clinical evidence and practical tools that help clinicians adopt new protocols and justify changes in procurement decisions.

Operationally, pursue supply chain de-risking through dual sourcing of critical ingredients, selective near-shoring, and enhanced digital compliance capabilities to navigate tariff and trade complexities. Collaborate with distribution partners to create flexible fulfillment models that span hospital pharmacy, online pharmacy, and retail pharmacy channels, and design packaging and dosing regimens optimized for dental clinics, hospitals, and home care environments. Finally, emphasize cross-functional alignment among medical affairs, regulatory, and commercial teams to translate evidence into clear labeling claims and adoption-ready educational programs that resonate with prescribers and procurement stakeholders.

These recommended actions will help organizations accelerate adoption, protect margins in changing policy contexts, and deliver therapies that align with contemporary priorities for efficacy, safety, and patient-centered recovery in dental care.

A transparent methodology combining clinician interviews, regulatory review, clinical literature synthesis, and operational validation to ensure evidence-driven conclusions

This research synthesizes primary expert interviews, peer-reviewed clinical literature, regulatory guidance documents, and validated operational intelligence to develop a robust evidence base. Primary insight was collected through structured interviews with dental clinicians, formulary managers, procurement leads, and manufacturing experts to capture practical perspectives across clinical, commercial, and supply chain domains. These qualitative inputs were triangulated with published clinical studies and regulatory guidance to validate therapeutic positioning, safety considerations, and administration preferences.

Operational data were drawn from industry-standard sources and validated vendor reports to map supply chain configurations, distribution channel dynamics, and manufacturing practices. Wherever possible, regulatory documentation and guidance from major health authorities were consulted to ensure that labeling considerations and safety monitoring requirements are accurately reflected. Throughout the methodology, data integrity checks, cross-source corroboration, and expert review were applied to ensure that conclusions reflect widely observed trends and actionable insights rather than isolated anecdotes.

The methodology emphasizes transparency in source types and analytic approaches and prioritizes clinician-validated interpretation of therapeutic roles, dosage forms, and route selection to ensure that recommendations are practicable within real-world dental settings.

Conclusion synthesizing clinical priorities, formulation innovation, regulatory nuance, and operational resilience to inform strategic decision making

Anti-inflammatory therapeutics for dental care occupy a strategic intersection of clinical need, formulation opportunity, and supply chain complexity. Clinicians are increasingly focused on multimodal approaches that prioritize patient safety, rapid recovery, and reduced reliance on systemic opioids, driving interest in localized formulations and well-defined administration protocols. Simultaneously, manufacturers and distributors must navigate regulatory scrutiny, tariff-induced supply chain shifts, and evolving channel dynamics to deliver differentiated products that are accessible across dental clinics, hospitals, and home care settings.

Success in this environment will favor organizations that couple clinical innovation with operational rigor: those that produce evidence-backed, dental-specific formulations and that execute resilient sourcing and distribution strategies. Clear alignment between medical affairs, regulatory, and commercial teams enhances the likelihood that new options reach patients efficiently and safely. Ultimately, the convergence of clinical priorities, regional regulatory nuance, and supply chain realities creates meaningful opportunities for stakeholders who can translate evidence into practice-ready solutions and reliably support clinicians across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-inflammatory Drugs for Dental Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Dexamethasone
    • 8.1.2. Prednisolone
  • 8.2. Nonsteroidal Anti-Inflammatory Drugs
    • 8.2.1. Ibuprofen
    • 8.2.2. Ketoprofen
    • 8.2.3. Naproxen

9. Anti-inflammatory Drugs for Dental Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Anti-inflammatory Drugs for Dental Market, by Dosage Form

  • 10.1. Gel
  • 10.2. Injection
  • 10.3. Mouthwash
  • 10.4. Tablet

11. Anti-inflammatory Drugs for Dental Market, by Application

  • 11.1. Periodontal Pain
  • 11.2. Postoperative Pain
  • 11.3. Preoperative Pain

12. Anti-inflammatory Drugs for Dental Market, by End User

  • 12.1. Dental Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Anti-inflammatory Drugs for Dental Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Anti-inflammatory Drugs for Dental Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-inflammatory Drugs for Dental Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-inflammatory Drugs for Dental Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-inflammatory Drugs for Dental Market

18. China Anti-inflammatory Drugs for Dental Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3M Company
  • 19.6. Church & Dwight Co. Inc.
  • 19.7. Colgate-Palmolive Company
  • 19.8. Dentsply Sirona Inc.
  • 19.9. GlaxoSmithKline plc
  • 19.10. Haleon plc
  • 19.11. Henry Schein Inc.
  • 19.12. Ivoclar Vivadent AG
  • 19.13. Johnson & Johnson
  • 19.14. Patterson Companies Inc.
  • 19.15. Pfizer Inc.
  • 19.16. Procter & Gamble Company
  • 19.17. Reckitt Benckiser Group PLC
  • 19.18. Septodont
  • 19.19. Sunstar Suisse S.A.
  • 19.20. VOCO GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)